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Summary 
Normal cells contain ~53 protein in a latent state that 
can be activated for sequence-specific transcription 
by low levels of UV radiation without an increase in 
protein levels. Microinjection of cells with an antibody 
specific to the C-terminal negative regulatory domain 
can activate the function of p53 as a specific transcrip- 
tion factor in the absence of irradiation damage, sug- 
gesting that posttranslational modification of a nega- 
tive regulatory domain in vivo is a rate-limiting step 
for p53 activation. Small peptides derived from the 
negative regulatory domain of ~53 have been used as 
biochemical tools to distinguish between allosteric 
and steric mechanisms of negative regulation of p53 
tetramer activity. Presented is the development of a 
highly specific peptide activation system that is con- 
sistent with an allosteric mechanism of negative regu- 
lation and that forms a precedent for the synthesis of 
novel low molecular mass modifiers of the ~53 re- 
sponse. 
Introduction 
p53 appears to play a central role in the cellular response 
to irradiation damage by activating an apoptotic or growth 
arrest pathway in proliferating cells (Maltzman and 
Czyzyk, 1984; Kastan et al., 1992; Kuerbitz et al., 1992; 
Hall et al., 1993; Lu and Lane, 1993; Zhan et al., 1993; 
Clarke et al., 1993; Lowe et al., 1993; Merritt et al., 1994; 
Yonish et al., 1991). The precise mechanism by which p53 
is activated by cellular stress is of intense interest and 
may involve both increases in p53 protein level and in the 
specific activity of p53 by covalent modification. Although 
direct activation of the latent sequence-specific DNA bind- 
ing activity of human ~53 can occur through ultraviolet 
(UV) light and serum-responsive signaling pathways in in- 
sect cell systems (Hupp and Lane, 1995), upstream intra- 
cellular signaling pathways involved in the direct activation 
of the biochemical function of p53 in mammalian cells 
following irradiation have not been clearly delineated, nor 
have the actual enzymes activating p53 function in vivo 
been identified. Biochemical analysis of p53 has shown 
that it interacts with many proteins implicated in regulation 
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of ~53 protein function, including protein kinases and 
phosphatases, heat shock proteins, and DNA binding pro- 
teins. The biochemical activity of p53 may also be regu- 
lated by interaction of the C-terminus with single stranded 
RNA or DNA (Oberosler et al., 1993; Bakalkin et al., 1994; 
Jayaraman and Prives, 1995). The activity of ~53 most 
tightly linked to its tumor suppressor activity is the ability 
of the protein to bind to DNA sequence-specifically (Kern 
et al., 1992; El-Deiry et al., 1992). Inactivating point muta- 
tions usually map within the active site for sequence- 
specific DNA binding or within the central core DNA bind- 
ing domain (Cho et al., 1994; Halazonetis and Kandil, 
1993; Bargonetti et al., 1993). Thus, sequence-specific 
DNA binding is a biologically relevant function of ~53, and 
understanding its regulation may reveal mechanisms 
whereby the cell regulates a key damage-responsive 
pathway. 
Biochemical analysis of the regulation of wild-type ~53 
sequence-specific DNA binding has shown that the un- 
phosphorylated tetramer has a cryptic sequence-specific 
DNA binding activity (Hupp et al., 1992). This cryptic or 
latent state of ~53 depends upon a C-terminal negative 
regulatory domain, which locks the unphosphorylated tet- 
ramer in an inactive state. Phosphorylation of the C-ter- 
minal negative regulatory domain of latent ~53 by either 
protein kinase C or casein kinase II (Hupp and Lane, 
1994b; Delphin and Baudier, 1994; Takenaka et al., 1995) 
or deletion of this regulatory domain (Hupp et al., 1992), 
activates sequence-specific DNA binding. In addition, a 
monoclonal antibody or bacterial heat shock protein 70 
(Hsp70), whose binding sites reside in the C-terminal neg- 
ative regulatory domain, mimic the affects of protein ki- 
nases and activate latent ~53 through a concerted transi- 
tion of subunits in the tetramer (Hupp and Lane, 1994a). 
Thus, neutralization of this negative regulatory domain by 
covalent or noncovalent modification is an important stage 
in the activation of ~53. 
To demonstrate directly that this activation pathway op- 
erates in mammalian cells, we show that the activation of 
p53 as a sequence-specific transcription factor following 
UV irradiation does not require increases in protein level 
and can be mimicked in vivo by the intranuclear microin- 
jection of antibody directed to the C-terminal negative reg- 
ulatory domain of ~53. In light of our results, we propose 
a model in which each C-terminal negative regulatory do- 
main interacts with a motif in the core of the tetramer and 
must be displaced to permit the specific DNA binding activ- 
ity of the protein. A prediction of this model, that small 
peptides derived from the C-terminal negative regulatory 
domain might interfere with this intra or intermolecular 
interaction and activate the DNA binding function of latent 
~53, is confirmed. Definition of the molecular details of 
this control pathway that regulates the cellular response 
to irradiation damage suggests the possibility of rational 
design of low molecular mass modifiers of the ~53 re- 
sponse. 
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Results 
UV-Induced Activation of the Transcriptional 
Function of p53 Does Not Require an Increase in 
p53 Protein Levels: Support for a Model of p53 
Activation by Posttranslational Modification 
The levels of ~53 protein rise dramatically in some cells 
and tissues exposed to DNA-damaging radiation (Maltz- 
man and Czyzyk, 1984; Kastan et al., 1991; Hall et al., 
1993; Midgley et al., 1995). This rise in ~53 protein follow- 
ing irradiation is associated with enhanced transcription 
of p53-responsive genes (Lu and Lane, 1993; Zhan et al., 
1993). Although the mechanism by which p53 levels in- 
crease in the environment of the irradiated cell is not 
known, the increase in p53 protein concentration provides 
a simple explanation for the increase in transcription from 
p53-responsive genes. However, an alternate mechanism 
forthe regulation of p53-dependent transcription has been 
suggested by a series of biochemical studies on the regu- 
lation of the sequence-specific DNA binding function of 
~53. These studies show that p53 can be produced in a 
biochemically latent state that can be activated for specific 
DNA binding after the modification of a C-terminal nega- 
tive regulatory domain by distinct enzymes in vitro (Hupp 
and Lane, 1994b). Furthermore, signaling pathways that 
respond to UV radiation or growth factors in serum can 
directly activate sequence-specific DNA binding function 
of p53 in cells (Hupp and Lane, 1995). According to this 
model, then, covalent modification of ~53 without increase 
in protein level may be sufficient to activate the ~53 re- 
sponse following DNA damage in normal cells. 
To test these two models, we used a wild-type p53 con- 
taining murine fibroblast cell line with a stably integrated 
p53-responsive (Ggalactosidase reporter gene. When these 
cells are exposed to intermediate doses of UV light (20 
and 40 J/m”) two events are observed: p53 levels rise, 
as judged by a sensitive enzyme-linked immunosorbent 
assay (ELISA) (Figure 1 A), and expression of the P-galac- 
tosidase reporter gene is activated as determined by cell 
staining (Figure 1B). Notably, the dose-response curve 
shows that at lower doses of UV irradiation (10 J/mZ), p53- 
dependent transcription is activated without any detect- 
able increase in p53 protein level (Figures 1A and 1B). 
These results imply that the specific activity of ~53 as a 
transcription factor can be altered by irradiation without 
increasing ~53 protein concentrations. In addition, these 
results suggest that unirradiated fibroblasts contain a pool 
of latent p53 that can be activated by a factor in response 
to DNA damage. To establish the existence of this pool 
of latent p53 in unirradiated cells, we sought to activate 
it independent of DNA damage. The antibody PAb421 is 
a potent activator of the DNA binding function of latent 
~53 in vitro, so we tested the capacity of the PAb421 anti- 
body to activate p53-dependent transcription in vivo by 
microinjection. 
Activation of the Sequence-Specific Transcriptional 
Response of p53 In Vivo by Microinjection of 
Antibody PAb421 Establishes the Existence of a 
Pool of Latent p53 in Mammalian Cells 
Strikingly, microinjection of the antibody PAb421 activates 
the p53 transcriptional response, as shown by the produc- 
tion of f3-galactosidase enzyme in the injected reporter 
cells (Figure 2ii). Buffer alone (Figure 2i), or an inhibitory 
antibody, PAb246 (Halazonetis and Kandil, 1993), does 
not give rise to a transcriptional response (Figure 2iii). A 
quantitative summary of two independent experiments is 
shown in Table 1. These results reflect an important con- 
cept, that a latent pool of ~53 can be activated in vivo in 
the absence of irradiation damage by a posttranslational 
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Figure 1. UV-Induced Activation of the Transcriptional Function of p53 Does Not Require an Increase in p53 Protein Levels 
(A) The level of p53 protein in extracts of the irradiated and unirradiated mouse fibroblast reporter cells was measured 16 hr after irradiation at 
the doses indicated by using a two-site ELISA in which p53 is captured with solid phase monoclonal antibody PAb248 and detected with rabbit 
anti-p53 antibody CM1 and an enzyme-labeled second antibody. The ELISA was standardized by titration of pure murine p53 protein. 
(6) The level of @galactosidase produced by p53 transcriptional activity was assessed at the single cell level by using an immunohistochemical 
method and the X-Gal substrate: (Bi), 0 J/m2; (Bii), 10 J/m2; (Biii), 20 J/m? (Biv), 40 J/m2. 
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Figure 2. Activation of the Sequence-Specific 
Transcriptional Response of ~53 In Vivo by Mi- 
croinjection of PAb421 
Cells were microiniected with control buffer 
(2i), the activating antibody PAb421 (2ii), or the 
inhibiting antibody PAb246 (2iii), incubated for 
16 hr, and then stained for 6-galactosidase pro- 
duction as in Figure 1. The complete results of 
two similar experiments are detailed in Table 1. 
event catalyzed by a specific agent targeting the C-ter- 
minal negative regulatory domain. Furthermore, they pro- 
vide an explanation of an earlier paradox in the field. While 
the viability of p53-null mice establishes unequivocally that 
~53 function is not required for the cell cycle, microinjec- 
tion of anti-p53 antibodies into the nuclei of quiescent cells 
has been shown to block entry of these cells into S phase 
following serum stimulation (Mercer et al., 1982, 1984; 
Deppert et al., 1990). These results had been interpreted 
previously to show that ~53 was required for entry into S, 
as it was reasonably assumed at the time that the antibod- 
ies acted as antagonists blocking an essential p53 function 
required for Gl exit. Our current results, based on our in 
vitro and in vivo studies, clearly demonstrate that these 
antibodies can instead act as agonists, activating the tran- 
scriptional activity of latent ~53 in vivo, and would therefore 
be expected to induce a p53-dependent Gl block in the 
same way as ionizing irradiation. Given the relevance of 
this activation reaction in vivo, we have focused on de- 
termining the mechanism of ~53 activation with a view 
toward identifying small molecules that can be used to 
regulate the ~53 pathway. 
A Synthetic Peptide Derived from the C-Terminal 
Regulatory Domain Activates Latent ~53 
Our current model of how the C-terminal negative regula- 
tory domain of ~53 acts to control the DNA binding function 
of ~53 is illustrated in Figure 8 (q.v.). Negative regulation of 
~53 may occur through amino acid side-chain interactions 
between the regulatory site and another domain within the 
tetramer. According to this allosteric model, competitive 
disruption of the regulatory site amino acid contacts by 
synthetic peptides derived from the C-terminus would lead 
to the conformational changes that activate ~53. In con- 
trast, according to a steric model of negative regulation, 
small peptide mimetics of the C-terminus would actually 
bind to the active site and inhibit sequence-specific DNA 
binding of ~53. To discriminate between these two possi- 
bilities, we sought to determine whether ~53 function 
would be inhibited or activated by small peptides derived 
from its negative regulatory domain. 
A panel of low molecular mass, overlapping polypep- 
tides derived from the C-terminal regulatory domain was 
used for these studies (Figure 3A). Peptide C, (C369-383), 
which harbors both the protein kinase C site and the 
Table 1. Quantitative Summary of Two Independent Experiments 
Injected Material 
6-Galactosidase-Positive Number of Cells 
Cells Injected 
Percent 6-Galactosidase-Positive 
Cells 
Experiment 1 
Buffer 15 105 14 
Buffer 3 117 3 
PAb 421 54 119 45 
PAb 421 75 181 41 
PAb 246 12 215 6 
PAb 246 6 70 9 
Experiment 2 
Buffer 17 216 a 
Buffer 14 164 7 
PAb 421 90 223 40 
PAb 421 47 166 26 
PAb 246 0 140 0 
PAb 246 3 204 2 
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Figure 3. Activation of the Sequence-Specific 
DNA Binding Function of Latent p53 by C-Ter- 
minal Synthetic Peptides 
(A) Binding sites of activating proteins within 
the C-terminal regulatory domain of ~53. The 
high affinity amino acid contacts required for 
+ 
+++ PAb421 (Stephen et al., 1995) and DnaK bind- 
+ ing (data not shown) and the sites of phosphor- + ylation of protein kinase C and casein kinase 
II are as indicated. The overlap and sequence 
of synthetic peptides C1-C,2, relative to the 
C-terminus of ~53, are also as indicated. Pep- 
tides C-C, are not biotinylated, while peptides C5-C12 contain an N-terminal biotin group linked to the amino acid sequence SGSG. The shaded 
amino acids depict high affinity amino acid contacts required for potent p53 activation, which is summarized on the left, from data in Figure 7. 
(B) Incubation of latent ~53 tetramers with synthetic peptides derived from the C-terminal regulatory domain. p53 protein (50 nM) was assembled 
in activation reactions with a panel of synthetic peptides as follows. Lane 1, no peptide; lanes 2-4, 1, 10, and 100 uM peptide C; lanes 5-7, 1, 
10, and 100 uM peptide C2; lanes 8-10, 1, 10, and 100 uM peptide Cs. After a 30 min incubation at 30°C, sequence-specific DNA binding was 
assayed at 0°C as indicated in the Experimental Procedures. 
363. 
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PAb421 epitope, activates ~53 at peptide concentrations 
of 100 FM (Figure 3B, lanes 2-4 versus lane 1). Synthetic 
peptides Cp (C364-378, lanes 5-7), CJ (C374-388, lanes 
8-10) or Cq (data not shown) at concentrations up to 100 
PM do not activate p53 function, indicating that activation 
by peptide C, is highly specific. These results are consis- 
tent with the model whereby specific amino acid contacts 
between the regulatory site and a surface subdomain can 
be disrupted to give rise to the allosteric activation of ~53. 
Synergistic Activation of Latent p53 by Use of 
Casein Kinase II and a Synthetic Peptide Derived 
from the Negative Regulatory Domain 
The activation of the latent sequence-specific DNA binding 
function of ~53 seen with peptide C, is modest. We sought 
to find conditions where the effect was enhanced so that 
we could examine the specificity of the activating peptides 
in more detail. Specifically, we have taken advantage of 
the fact that, under specific conditions, stoichiometric 
12 3 4 5 6 7 8 91011 
B 
phosphorylation of wild-type ~53 can be uncoupled from 
its activation (see below, Figure 8). 
The rate of p53 activation by casein kinase II was ana- 
lyzed by using catalytic levels of recombinant casein ki- 
nase II (lo-fold lower molar equivalents); underthese reac- 
tion conditions, p53 becomes progressively more active 
from 2-10 min at 30°C (Figure 4A, lanes l-5), despite 
the fact that stoichiometric phosphorylation has occurred 
within 30 s (Figure 4B). These results indicate that phos- 
phorylation by recombinant casein kinase II is avery rapid 
step and that subsequent conformational changes leading 
to p53 activation are rate limiting. 
Under these conditions, in which there is a lower level 
of ~53 activation, but stoichiometric phosphorylation of 
the protein, the subsequent addition of peptide C, at 0% 
dramatically stimulated ~53 sequence-specific DNA bind- 
ing (Figure 4A, lanes 7-l 1) to achieve a specific activity 
similar to PAb421-activated ~53 (data not shown). The 
N-terminal antibody DO-1 shifts the migration of this pro- 
?---- 
1 
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Figure 4. Synergistic Activation of p53 by Phosphorylation and C-Terminal Peptide Addition 
(A) Synergistic activation of phospho-p53 with a synthetic peptide derived from the C-terminal regulatory domain. p53 (50 nM) was left unphosphory- 
lated (lanes 1 and 6) or phosphorylated at 30°C with recombinant human casein kinase II (Hupp et al., 1993), 2 ng for 1 min. After phosphorylation, 
the reactions were incubated further for 1, 2,5, and 10 min at 30%. Subsequently, peptide C, (20 FM) was added (lanes 6-l 1) during DNA binding 
at 0% and products were analyzed as indicated in the Experimental Procedures. The N-terminal antibody DO-l was added to a parallel reaction 
(lane 11 versus lane 7) to demonstrate ~53 specificity and tetrameric nature when bound to DNA. 
(B) Rate of p53 phosphorylation by casein kinase II. p53 (50 nM) was incubated with recombinant human casein kinase II for the indicated time 
in reactions containing [yJ2P]ATP, and phosphate incorporated into p53 was determined as indicated previously (Hupp et al., 1992). 
(C) Peptide titration in activation of phospho-p53 tetramers. p53 (50 nM) was phosphorylated with casein kinase II (2 ng) for 1 min at 30°C (lanes 
I-12) or was left unphosphorylated (lanes 13-15). Subsequently at O°C, either peptide C, (lanes 2-5; 5, 10, 20, or 40 PM), potassium chloride 
(lanes 6-9; 50, 100, 150, and 200 mM), DnaK (lanes 10-12; 1.4, 2.8, or 5.6 pM protein) or peptide C1 (lanes 13-15; 10, 20, or 40 FM) were added, 
and DNA binding was assayed as indicated in Experimental Procedures. 
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tein-DNA complex (lane 11 versus lane 7), demonstrating 
the ~53 specificity of the reaction. In addition, the tetra- 
merit nature of this peptide-activated form of ~53 (lane 
11) is clear from the expression of four DO-1 epitopes 
bound by two DO-1 monoclonal antibodies during native 
gel electrophoresis, as described previously (Hupp and 
Lane, 1994a). 
Alterations in ionicstrength (Figure4C, lanes6-9versus 
lane 1) or addition of bacterial Hsp70 (lanes 1 O-l 2 versus 
lane 1) could not lead to a stimulation of sequence-specific 
DNA binding of latent, phospho-p53 intermediate com- 
plexes. Under these same conditions, a prior, rapid, and 
stoichiometric phosphorylation of p53 was essential to un- 
mask the highest level of stimulation of sequence-specific 
DNA binding by the synthetic peptide (lanes 2-5 versus 
lanes 13-15). 
Synergistic Activation of Latent ~53 by Use of DnaK 
and a Synthetic Peptide Derived from the 
Negative Regulatory Domain 
To gain further insight into the activation of ~53 by syn- 
thetic peptides, we investigated whether a prior modifica- 
tion of the C-terminal regulatory site of ~53 by a nonkinase 
activator could also give rise to synergistic activation by 
peptides. This second assay takes advantage of the facts 
first that the Escherichia coli Hsp70 protein (DnaK) can 
also interact with latent ~53 tetramers to unmask the cryp- 
tic sequence-specific DNA-binding activity efficiently in 
vitro (Hupp et al., 1992, 1993); second, that DnaK targets 
the C-terminal negative regulatory domain at a site within 
peptide Cs (data not shown); and third, that activation of 
~53 by DnaK can now be divided into two stages; a latent 
DnaK-p53 intermediate complex can be stably isolated 
at 0% (see below). 
Activation of latent ~53 by DnaK requires an incubation 
at 30°C, as activation of ~53 does not occur when reac- 
tions are incubated at 0°C (Figure 5, lane 6). As DnaK 
does not activate ~53 at O%, the ability of peptide C, to 
synergize in concert with DnaK under these conditions 
was examined. Importantly, and in contrast with peptide 
CJ, the activating peptide C, does not bind to DnaK (data 
Figure 5. Activation of Latent ~53 with Peptide C, and DnaK 
p53 protein (50 nM) was assembled in activation buffer with increasing 
amounts of peptide C, alone (lanes 1-5; 0 uM, 12 PM, 25 vM, 50 
KM, and 100 PM, respectively) or with DnaK (2.8 vM) and increasing 
amounts of peptide C, (lanes 6-10; 0 PM, 12 PM, 25 PM, 50 PM, and 
100 vM, respectively) at 0% for 30 min. After the addition of DNA 
binding buffer and radiolabeled DNA, products were analyzed as indi- 
cated in Experimental Procedures. 
not shown). As seen previously, a titration of peptide C,, 
in the absence of DnaK at O°C, gives rise to a modest 
activation of latent ~53 (Figure 5, lanes l-5). In contrast, 
a titration of peptide C,, in the presence of DnaK at 0% 
(Figure 5, lanes 7-10 versus lane 6), gives rise to a dra- 
matic activation of latent ~53 with an apparent K, of 
peptide activation being 32 PM. The specific activity of 
DnaK-peptide-activated ~53 at 0% was identical to that 
of DnaK-activated ~53 at 30°C (data not shown). Alter- 
ations in the pH, ionic strength, or time of incubation does 
not lead to a DnaK-dependent activation of ~53 at 0% in 
the absence of peptide (data not shown). 
Alanine Scan of the Activating Peptide Defines 
Specific Amino Acids Required to Activate 
Latent Forms of ~53 
Truncation of the activating peptide defines endpoints re- 
quired for activation of ~53. A panel of biotinylated pep- 
tides that contain N-terminal or C-terminal deletions of the 
activating peptide Cr (a biotinylated version of the activat- 
ing peptide C,; see Figure 3) was used to define the end 
limits required for peptide activation with DnaK at 0%. A 
titration of peptide C7 activates p53 by using DnaK with 
an apparent K, of activation being 9 FM (Figure 6), which 
is approximately 4-fold lower than that obtained with the 
nonbiotinylated peptide C, in the presence of DnaK. Trun- 
cated derivatives of the full-length peptide, peptides CS 
and Cs, could also coactivate with DnaK, but the apparent 
K, of activation was slightly higher at 30 PM. However, 
further truncation from the N-terminus (peptide GO or CW) 
or from the C-terminus (peptide C,,) prevented peptide 
activation, thus defining N- and C-terminal endpoints re- 
quired for high affinity activation of ~53. 
A series of peptides with single alanine substitutions 
at every position from amino acids 369-383 was used to 
define critical amino acids within the full-length peptide 
that function in the activation of ~53 (Figure 7). These 
results define a consensus polypeptide sequence that 
plays an essential role in the rate-limiting activation of ~53. 
Specifically, substitution of any of the positively charged 
amino acids (K370, K372, K373, R379, K381, or K382) 
with alanine dramatically reduces the ability of the 19 
amino acid synthetic peptide to activate p53 potently. Sub- 
Figure 6. Truncation of Activated Peptide Defines Endpoints Re- 
quired for High Affinity Activation 
Activation reactions ware assembled containing ~53 (50 PM), DnaK 
(2.8 pM), and the indicated synthetic peptides containing truncations 
(as indicated in Figure 3) at 0% for 30 min. After the addition of DNA 
binding buffer and radiolabeled DNA, products were analyzed as indi- 
cated in Experimental Procedures. 
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Figure 7. Alanine Substitution of the Activating Peptide Defines Es- 
sential Amino Acid Contacts 
Activation reactions were assembled containing p53 (50 nM), DnaK 
(2.6 FM), and synthetic peptides (30 PM) containing alanine substitu- 
tions at the indicated positions of 1 through 16). Lane 17 represents 
peptide-16/DnaK-activated p53-DNA complexes shifted by DO-l, 
demonstrating the tetrameric nature of ~53. 
stitutions of the remaining nine amino acids with alanine 
are tolerated and do not dramatically reduce the apparent 
K, of activation. These results begin to define the exact 
molecular requirements and assay conditions to develop 
low molecular mass regulators of the p53 allosteric activa- 
tion pathway. 
A Rate-Limiting Step in the Activation of ~53 
Sequence-Specific Transcriptional 
Function In Vivo 
Prior to these studies, key chemical steps involved in di- 
rectly activating p53 protein following DNA damage in 
mammalian cells have been undefined. However, the abil- 
ity to activate the sequence-specific transcriptional func- 
tion of wild-type p53 in vivo, by using a monoclonal anti- 
body(PAb421) known to activate the specific DNA binding 
function of ~53 in vitro, underscores the rate-limiting role 
of this allosteric activation reaction in modulating the p53 
pathway. These data establish the presence of a pool of 
latent ~53 that can be activated posttranslationally in nor- 
mal cells and demonstrate that the activation of p53- 
responsive reporter genes can occur in the absence of 
other signals that might be mediated by DNA damage 
within the cells, i.e., direct effects on the template DNA. 
Indeed, a p53-dependent superinduction of ~21~‘~’ mRNA 
was observed upon serum stimulation of quiescent wild- 
type fibroblasts in the presenceof cycloheximide(Macleod 
et al., 1995), suggesting that activation of p53 transcrip- 
tional function can occur in the absence of protein synthe- 
sis In addition, the fact that modification of ~53 in the 
C-terminal negative regulatory domain resulting in loss of 
the antibody PAb421 epitope (Milner, 1984; Ullrich et al., 
1992; Hupp and Lane, 1995) or alternative splicing of 
mouse p53 mRNA resulting in removal of the negative 
regulatory domain occurs in tissue culture systems (Arai 
et al., 1986; Kulesz-Martin et al., 1994) indicates that modi- 
fication of the negative regulatory domain can occur in 
vivo in the absence of DNA damage. 
That activation of the transcriptional activity of ~53 can 
occur without an increase in p53 protein levels is consis- 
tent with the existence of distinct cellular signaling path- 
ways capable of modulating theconversion between latent 
and activated forms of p53 (Hupp and Lane, 1995). The 
results also explain how microinjection of antibodies to 
the C-terminus of ~53 can block cell cycle progression 
(Mercer et al., 1982, 1984; Deppert et al., 1990) by virtue 
of activating the biochemical function of endogenous p53 
protein. As such, determining the mechanism of ~53 acti- 
vation may have future therapeutic relevance. Selective 
activation of wild-type p53 by agents that do not induce 
DNA damage may differentially alter the response of nor- 
mal tissue as compared with that of p53-negative tumor 
cells to therapeutic agents toxic only to rapidly cycling 
tumor cells. On the other hand, one class of mutation in 
~53 results in proteins that cannot be activated after phos- 
phorylation, but can be activated in vitro by binding of 
the activating monoclonal antibody PAb421 (Hupp et al., 
1993; Niewolik et al., 1995). The latter study is notable, 
as almost one third of the mutant forms of p53 synthesized 
in human tumor cell lines can be activated in vitro by the 
binding of PAb421, suggesting that aconsiderable propor- 
tion of human tumors might respond to allosteric activators 
by rescuing their p53 response. 
An Allosteric Model for the Activation of p53 
The mechanism of p53 latency and the mechanism 
whereby the protein is activated after covalent modifica- 
tion are not known. In addition, neither the crystal structure 
of the full-length unphosphorylated p53 tetramer nor that 
of the phosphorylated tetramer are known, thus precluding 
predictions on the mechanisms of latency and activation. 
However, using synthetic peptides derived from the C-ter- 
minal negative regulatory domain of ~53, we have defined 
a small molecule that can activate latent p53 function, and 
this information has led to a specific biochemical model 
reflecting a possible mechanism of ~53 latency and a 
mechanism whereby phosphorylation alters polypeptide 
structure. The key elements of this model are that the 
C-terminal tails of p53 interact with the core of the molecule 
(Figure 8). This interaction locks the core into a conforma- 
tion that is inactive for DNA binding. When this tail-core 
interaction is disrupted by covalent modification, noncova- 
lent modification, or deletion, the core is then able to adopt 
the active form. Complete activation of ~53 is not accom- 
plished effectively by synthetic polypeptides alone, sug- 
gesting that negative regulatory domain interactions are 
not easily disrupted. The stability of the negative regula- 
tory domain interactions are also manifested in the ability 
to purify to homogeneity latent p53 tetramers by using 
three sequential chromatographic matrices (Hupp and 
Lane, 1994a); i.e., a spontaneous shift in equilibrium from 
the latent to activated state during purification would have 
reduced latent tetramer yield if ~53 negative regulatory 
domain-tetramer interactions were of low affinity and sub- 
ject to destabilization. 
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Figure 9. Model for Peptide Activation of Latent p53 Tetramers 
p53 exists stably in the latent state owing to interactions between 
the basic negative regulatory domain amino acid side chains (shaded 
cylinders) and a peptide-binding pocket within the tetramer. Deletion 
of the regulatory domain or its phosphorylation and subsequent incu- 
bation at high temperature (30%) disrupts regulatory domain interac- 
tions and converts the latent tetramer to an activated tetramer through 
aconcerted transition ofsubunits. Activation byposttranslational modi- 
fication at the regulatory site can now be separated into two stages. 
The first step is a rapid event in which the regulatory domain is modified 
(i.e., by covalent modification), but the energy barrier required to dis- 
rupt the regulatory domain-tetramer interaction is not overcome. As 
a result, a stable and latent phospho-intermediate can be isolated. 
However, in a rate-limiting stage, the activating peptide (darkened 
cylinder) can effectively compete with the phosphorylated regulatory 
domain bindingsiteatOV, promotingthedissociationofthephosphor- 
ylated C-terminus from its binding site and thus inducing the conforma- 
tional change required to activate the tetramer for sequence-specific 
DNA binding. 
Although the activating peptide was not able to activate 
latent ~53 potently, a striking decrease in the apparent 
K, for peptide activation and an increase in the specific 
activity of ~53 was accomplished by a prior modification 
of the C-terminus by casein kinase II or interactions with 
the heat shock protein DnaK under conditions in which 
activation is rate limiting. This modification presumably 
primes p53 protein and decreases the energy barrier to 
peptide activation by shifting the equilibrium to a state 
more favorable to stabilize synthetic peptide-tetramer in- 
teractions (Figure 8). This model is also supported by the 
existence of mutant forms of ~53 that can be activated 
from their latent state by the PAb421 monoclonal antibody, 
but cannot be activated after phosphorylation of its nega- 
tive regulatory domain (Hupp et al., 1993). Thus, a single 
point mutation in the core domain of p53 can stabilize 
C-terminal negative regulatory domain interactions and 
hinder activation by covalent modification. 
Peptide synergism with activating factors also questions 
the reliability of using immunoaffinity-purified p53 to inter- 
pret biochemical studies on its posttranslational regula- 
tion lmmunoaffinity purification of p53 using a PAb421 
antibody-linked matrix utilizes a peptide similar to the acti- 
vating peptide C, (Figure 3) to elute p53 from the antibody 
column (Sargonetti et al., 1993). That specific peptides 
can synergize with p53-activating factors (Figures 4-6) 
indicates that conclusions based on studies of regulation 
of ~53 by enzymes may be misleading, owing to contami- 
nation of protein preparations with the peptides. 
The allosteric model of negative regulation can also be 
used to predict that reduction in net basic charge in the 
vicinity of the C-terminal regulatory site would be destabi- 
lizing and could displace the negative regulatory domain 
from its binding site. Apart from phosphate modification, 
three other independent experiments support this predic- 
tion. First, site-directed mutagenesis producing the substi- 
tution of four basic amino acid residues with hydrophobic 
amino acids from the C-terminal negative regulatory do- 
main has already been shown to increase strikingly the 
specific activity of p53 as a sequence-specific transcrip- 
tional activator in vivo (Tarunina and Jenkins, 1993), pre- 
sumably by allowing spontaneous activation of p53 during 
tetramer assembly in cells. These latter results are strik- 
ing, especially as this quadruple regulatory site mutant 
form of ~53 actually has a higher specific activity than ~53 
activated by deletion of its negative regulatory domain. 
Second, a monoclonal antibody, which binds to the acidic 
domain in the extreme C-terminus, cannot activate ~53 
and appears actually to stabilize negative regulatory do- 
main interactions (Hupp and Lane, 1994a). Third, by an 
elegant approach, random mutagenesis of the C-terminus 
of human p53 and subsequent screening for mutants that 
have lost sequence-specific transcriptional activity in 
yeast model systems resulted in acquisition of two inde- 
pendent point mutations in the casein kinase II site at 
amino’ acid 393 that increased net basic charge (Ishioka 
et al., 1995), an expected result if maintenance of net basic 
charge is an important element in contributing to p53 la- 
tency. 
In conclusion, peptide-dependent activation provides 
the opportunity to formulate biochemical models of p53 
latency that can be tested experimentally and thus shed 
new light on the role phosphorylation plays in allosterically 
altering polypeptide conformation. These studies also 
hold promise for the design of low molecular mass agents 
that can also activate mutant forms of ~53 defective in 
allosteric activation by protein kinases, as activation of 
wild-type ~53 can now be shown in vivo by use of a mono- 
clonal antibody. 
Experimental Procedures 
Reagents, Enzymes, and Proteins 
Recombinant latent forms of human ~53, casein kinase II from rabbit 
muscle, DnaK, and monoclonal antibodies DO-l, PAb421-Fab frag- 
ments, and PAb421 were purified as described (Hupp and Lane, 
1994a; Hupp et al., 1992). Assembly of activation reactions, sequence- 
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specific DNA-binding reactions, ELISA, DnaK and p53 peptide-binding 
reactions, and phosphorylations were performed as indicated in the 
figure legends. Recombinant human casein kinase II was obtained 
from Boehringer Mannheim. Synthetic peptides were obtained from 
Pfizer and Chiron Mimitopes. 
Activation of p53 
p53 (indicated amounts) was added to 10 ~1 of activation buffer (10% 
glycerol, 1 .O mglml BSA, 0.05 M KCI, 0.1 mM EDTA, 5 mM DTT, 0.05% 
Triton X-100,10 mM MgCI,, 0.5 mM ATP [or 50 PM ATP when activated 
with protein kinases] and 25 mM HEPES [pH 7.6]), followed by incuba- 
tion at 30°C for 30 min with indicated activating factor or peptide. 
Reactions were placed at O°C with 10 PI of a DNA binding buffer (20% 
glycerol, 1.0 mglml BSA, 0.05 M KCI, 0.1 mM EDTA, 5 mM DTT, 
0.05% Triton X-100, 10 mM MgCI,, 0.5 mM ATP, 5 ng of radiolabeled 
consensus site oligonucleotide [Hupp et al., 19921) and 100 ng of 
supercoiled pBluescript competitor DNA. Reaction products were pro- 
cessed by using native gel electrophoresis as indicated previously 
(Hupp et al., 1992). 
DNA Transfections and UV Treatment 
RGCAFos LacZ plasmid DNA (IO Kg) and DOR neo2 plasmid DNA 
(1 vg) were cotransfected into 5 x 1 O5 cells (B-galactosidase cells) by 
calcium phosphate precipitation followed by a 15% glycerol shock. 
The transfected cells were cultured in selection medium supplemented 
with 1 Kg/ml G418 (b-galactosidase cells) to select cells containing 
neo plasmid. Fourteen resistant cells were cloned by cloning ring and 
expanded. The b-galactosidase activity was measured 12 hr after the 
cells were exposed to IO J/m* of UV to induce the endogenous wild- 
type ~53, and the most responsive clone was used to carry out further 
study. When cells had grown to 80% confluence, in Dulbecco’s Modi- 
fied Eagle’s Medium (DMEM) supplemented with 10% fetal calf serum 
(FCS) and 1 pglml G418, culture medium was removed, and the cells 
were exposed to UV in an XL-1500UV cross-linker (Spectronics Corpo- 
ration). The energy of UV light delivered was precisely controlled by 
the cross-linker. After exposure, the cells were grown in fresh culture 
medium for 16 hr before LacZ expression was determined. Cells were 
then washed with phosphate-buffered saline (PBS) and fixed with 2% 
formaldehyde, 0.2% glutaraldehyde in PBS for 5 min on ice. Cells 
were washed with PBS and overlaid with 0.25 mglml X-Gal in reaction 
mix (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 
mM magnesium chloride in PBS). Cells were incubated at 37OC for 
16 hr and b-galactosidase-positive cell numbers determined. 
Murine p53 ELBA 
Levels of murine p53 were determined in a two-site immunoassay as 
follows. Falcon microtiter dish wells were coated with 50 PI of purified 
mouse monoclonal antibody PAb248 at 30 pglml in carbonate coating 
buffer for 8 hr at 4°C. The capture antibody was then removed and 
the plates blocked with 200 ~1 of 3% BSA in PBS overnight at 4°C. 
The plates were washed (1 x PBS, 2 x 0.1% NP-40 in PBS, 1 x PBS) 
and 50 ~1 of serially 2-fold-diluted cell extract added for 3 hr at 4OC. 
Cell extracts were prepared by lysis in ice-cold NET buffer (50 mM 
Tris-HCI [pH 8.01, 150 mM NaCI, 5 mM EDTA, 1% NP-40) containing 
2 mM phenylmethylsulfonyl fluoride, for 30 min at 4°C. Debris was 
removed from the lysate by centrifugation at 14,000 rpm in a refriger- 
ated Eppendorf centrifuge. Cell lysates were removed, avoiding cross- 
contamination, and the plates washed as before. Captured murine 
p53 was detected by using 50 I.LI of the rabbit anti-p53 serum CM1 
diluted 1:lOOO in 1% BSA in PBS for 2 hr at 4OC. The plates were 
washed, and 50 pl of horseradish peroxidase-conjugated swine anti- 
rabbit IgG diluted I:1000 in 1% BSA in PBS was added for 2 hr at 
4OC. Following washing, bound p53 was visualized with 50 ~1 of TMB 
substrate per well. The color reaction was stopped by the addition of 
50 ~1 of 1 M H2S04 per well and the optical density at 450 nm measured. 
The murine p53 ELISA was standardized by including known quanti- 
ties of recombinant murine p53 expressed in E. coli and resolubilized 
from inclusion bodies. 
Microinjection 
Prior to microinjection (24 hr beforehand), the cells were trypsinized, 
and approximately 200 cells were spotted as 5 ~1 drops onto tissue 
culture dishes. Cells were allowed to adhere for 1 hr before culture 
medium was added. Microinjection was performed with an Eppendorf 
microinjection system (Microinjector 5242, Micromanipulator 5170) 
mounted to an Axiovert 35 M with heated stage. Injections were intra- 
nuclear. Purified mouse monoclonal antibodies PAb421 and PAb246 
were injected in microinjection buffer (100 mM glutamic acid, 140 mM 
KOH, 1 mM MgSO, [pH 7.21) at a concentration of 2 mglml. Following 
microinjection, fresh medium was added to the cell cultures, and they 
were incubated 24 hr before being fixed and assayed for LacZ expres- 
sion with X-Gal. 
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